Clinical trials
EGFR clinical trials
Below are recruiting egfr clinical trials, each written for real people, not researchers. We’re tracking 239 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03198052RecruitingPhase 1
CAR-T cell therapy for cancers with specific protein targets
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
Guangzhou, GuangdongAges 18–75 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT07814287RecruitingPhase 2
New drug combo for advanced EGFR-positive head and neck cancer
This trial tests a new combination of drugs for a type of head and neck cancer that has a specific protein called EGFR. The treatment combines an antibody-drug conjugate, an immunotherapy, and standard chemotherapy. The goal is to see if this combination shrinks or controls the cancer before possible surgery.
Guangzhou, GuangdongAges 18–70 - NCT07806604Recruiting
Icotinib after surgery for early lung cancer with EGFR mutation
This trial studies a pill called icotinib, given after lung cancer surgery, to see if it helps prevent the cancer from returning in people with early-stage, EGFR-mutant non-small cell lung cancer. It is a real-world study, meaning it looks at how the treatment works in routine practice.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07790510RecruitingPhase 1/Phase 2
Study of HSK42360 with cetuximab for BRAF-mutated colorectal cancer
This trial tests an experimental drug (HSK42360-Na) combined with standard treatments (cetuximab with or without chemotherapy) for people with advanced colorectal cancer that has a specific BRAF mutation. The goal is to see if this combination can shrink tumors or slow their growth, and to check its safety.
BeijingAges 18 years+ - NCT07768189RecruitingPhase 3
Testing CRB-701 for throat cancer that returned
This study tests an investigational drug called CRB-701 to see if it can help people with a certain type of throat cancer that has not responded to standard treatments. The trial compares CRB-701 to a doctor's choice of other available treatments.
Huntsville, AlabamaAges 18 years+ - NCT07774520RecruitingPhase 2
Lower dose of lazertinib plus magnesium to prevent nerve damage in advanced lung cancer
This trial tests a lower starting dose of the targeted therapy drug lazertinib combined with magnesium supplements to prevent a common side effect (peripheral neuropathy) in people with advanced lung cancer caused by certain EGFR mutations. The goal is to see if this approach keeps the drug effective while reducing nerve damage symptoms like numbness or tingling.
Seoul, Gang-nam GuAges 19 years+ - NCT06348927RecruitingPhase 2
Sunvozertinib plus anlotinib for first-line EGFR-mutant lung cancer
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
Changsha, HunanAges 18 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT06355609RecruitingPhase 2
Targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
Changsha, HunanAges 18 years+ - NCT07744529RecruitingPhase 1/Phase 2
Combination treatment for lung cancer spread to the lining of the brain
This trial tests a new combination of two drugs for people with a specific type of lung cancer that has spread to the lining of the brain and spinal cord. The treatment aims to target the cancer cells and may help improve symptoms and survival.
Hangzhou, ZhejiangAges 18 years+ - NCT07738172RecruitingPhase 3
Osimertinib with or without lung tumor surgery for EGFR-mutated non-small cell lung cancer
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
Taipei, Taipei CityAges 18 years+ - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT04322890RecruitingPhase 2
Study for advanced lung cancer with gene mutations
This Phase 2 trial studies treatment strategies for people with stage IV non-small cell lung cancer (NSCLC) who have certain cancer gene mutations (like EGFR, ALK, or ROS1). It aims to see how different treatments affect survival and tumor response.
Changsha, HunanAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT07696832Recruiting
Ivonescimab as first treatment for advanced lung cancer
This trial studies ivonescimab alone as a first treatment for people with advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1 and doesn't have certain gene changes. The goal is to see if it works and is safe in everyday medical practice.
Guangzhou, GuangdongAges 18 years+ - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07665190RecruitingPhase 2
New drug combination before surgery for advanced throat cancer
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07655622RecruitingPhase 1/Phase 2
Vebreltinib and furmonertinib for advanced EGFR-mutant lung cancer with high PD-L1
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
Nanchang, JianxiAges 18–75 - NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07641023RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Lung Cancer
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
Shenzhen, GuangdongAges 18–75 - NCT07640789RecruitingPhase 3
BL-B01D1 plus osimertinib for advanced lung cancer after chemotherapy
This study tests whether adding a new drug called BL-B01D1 to osimertinib (a targeted lung cancer medicine) works better than osimertinib alone. You may qualify if you have advanced lung cancer with an EGFR mutation that didn't get worse after chemotherapy and radiation treatment.
Jinan, ShandongAges 18–75 - NCT06269211RecruitingPhase 2
Immunotherapy before surgery for EGFR-mutated lung cancer
This trial tests whether giving an immunotherapy drug (toripalimab) before surgery can help people with a specific type of lung cancer (EGFR-mutated, PD-L1 positive) that can be removed. The goal is to see if it improves treatment results compared to surgery alone.
Guangzhou, GuangdongAges 18 years+ - NCT07624487RecruitingPhase 2
Aumolertinib and chemotherapy for EGFR L858R lung cancer
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
New Taipei CityAges 18 years+
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for egfr?
- Yes. Clin2 currently lists 239 recruiting egfr studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a egfr trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a egfr trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.